DOD Biotech PCL (DOD.BK) Stock Price

DOD Biotech PCL Price

CLOSED
1.13THB-0.0100 (-0.88 %)
Market closed

Revenue has compounded at 60.6% per year over the past 12 years to 608.98 M THB. Earnings per share have declined at 9.2% per year over the last 9 years. DOD Biotech PCL's net margin stands at 9.8%, down from 23.0% several years earlier. DOD Biotech PCL currently offers a dividend yield of about 4.42%. The payout ratio is around 15% of earnings. The stock trades about 4% above its 52-week low.

DOD Biotech PCL stock price

Volume
Ex-Dividend
Details

Stock Price

ⓘ

How to Read This Chart

This chart tracks the historical stock price of DOD Biotech PCL over time. You can switch between daily, weekly, and monthly views and select custom time ranges — from a single day to the full available history. Use the toggle to view price changes in absolute currency terms or as a percentage change relative to the starting date.

Total Return vs. Price Return

The "Total Return" toggle includes reinvested dividends on top of the pure price movement. This is critical because dividends can account for a significant portion of long-term returns. Historically, roughly 40 % of the S&P 500's total return has come from dividends. Always compare total return when evaluating a stock's real performance against a benchmark.

Intraday Price Data

When viewing a one-day time frame, the chart displays real-time intraday price movements. This is useful for observing how DOD Biotech PCL stock reacts to market openings, earnings releases, or breaking news throughout the trading session.

What to Look For

Look for long-term trends (sustained upward or downward movements over months and years), support and resistance levels (price zones where the stock repeatedly bounces or reverses), and volatility (how much the price fluctuates day to day). Comparing DOD Biotech PCL's price chart to a market index like the S&P 500 can reveal whether the stock is outperforming or underperforming the broader market.

DOD Biotech PCL Stock Price History
DateDOD Biotech PCL Price
7/31/20261.13 THB
7/30/20261.14 THB
7/29/20261.16 THB
7/28/20261.16 THB
7/27/20261.16 THB
7/24/20261.16 THB
7/23/20261.15 THB
7/22/20261.16 THB
7/21/20261.18 THB
7/20/20261.17 THB
7/17/20261.18 THB
7/16/20261.18 THB
7/15/20261.18 THB
7/14/20261.16 THB
7/13/20261.16 THB
7/10/20261.16 THB
7/9/20261.15 THB
7/8/20261.16 THB
7/7/20261.18 THB
7/6/20261.19 THB
7/3/20261.19 THB
7/2/20261.16 THB
7/1/20261.28 THB
6/30/20261.29 THB
6/29/20261.09 THB
6/26/20261.50 THB
6/25/20261.50 THB
6/24/20261.50 THB
6/23/20261.49 THB
6/22/20261.56 THB
6/19/20261.55 THB
6/18/20261.60 THB
6/17/20261.60 THB
6/16/20261.58 THB
6/15/20261.60 THB
6/12/20261.59 THB
6/11/20261.59 THB
6/10/20261.59 THB
6/9/20261.63 THB
6/8/20261.62 THB
6/5/20261.64 THB
6/4/20261.65 THB
6/3/20261.64 THB
6/2/20261.64 THB
6/1/20261.64 THB
5/29/20261.64 THB
5/28/20261.66 THB
5/27/20261.64 THB
5/26/20261.68 THB
5/25/20261.68 THB
5/22/20261.64 THB
5/21/20261.62 THB
5/20/20261.63 THB
5/19/20261.65 THB
5/18/20261.64 THB
5/15/20261.66 THB
5/14/20261.65 THB
5/13/20261.65 THB
5/12/20261.67 THB
5/11/20261.68 THB
5/8/20261.69 THB
5/7/20261.72 THB
5/6/20261.70 THB
5/5/20261.63 THB
5/4/20261.64 THB
5/1/20261.64 THB
4/30/20261.64 THB
4/29/20261.64 THB
4/28/20261.63 THB
4/27/20261.66 THB
4/24/20261.70 THB
4/23/20261.71 THB
4/22/20261.72 THB
4/21/20261.71 THB
4/20/20261.69 THB
4/17/20261.70 THB
4/16/20261.73 THB
4/10/20261.74 THB
4/9/20261.74 THB
4/8/20261.76 THB
4/7/20261.74 THB
4/3/20261.77 THB
3/27/20261.72 THB
3/26/20261.74 THB
3/25/20261.73 THB
3/24/20261.67 THB
3/23/20261.67 THB
3/20/20261.73 THB
3/19/20261.74 THB
3/18/20261.85 THB
3/17/20261.84 THB
3/16/20261.74 THB
3/13/20261.75 THB
3/12/20261.79 THB
3/11/20261.73 THB
3/9/20261.67 THB
3/6/20261.73 THB
3/5/20261.75 THB
2/26/20261.80 THB
2/25/20261.80 THB
2/24/20261.82 THB
2/23/20261.69 THB
2/20/20261.82 THB
2/19/20261.87 THB
2/18/20261.88 THB
2/17/20261.87 THB
2/16/20261.85 THB
2/13/20261.83 THB
2/12/20261.87 THB
2/11/20261.88 THB
2/10/20261.83 THB
2/9/20261.82 THB
2/6/20261.55 THB
2/5/20261.52 THB
2/4/20261.50 THB
2/3/20261.51 THB
2/2/20261.53 THB
1/30/20261.56 THB
1/29/20261.57 THB
1/28/20261.56 THB
1/27/20261.57 THB
1/26/20261.49 THB
1/23/20261.52 THB
1/22/20261.55 THB
1/21/20261.57 THB
1/20/20261.57 THB
1/19/20261.53 THB
1/16/20261.51 THB
1/15/20261.50 THB
1/14/20261.49 THB
1/13/20261.52 THB
1/12/20261.48 THB
1/9/20261.54 THB
1/8/20261.55 THB
1/7/20261.57 THB
1/6/20261.57 THB
1/5/20261.62 THB
12/30/20251.62 THB
12/29/20251.62 THB
12/26/20251.63 THB
12/25/20251.62 THB
12/24/20251.63 THB
12/23/20251.65 THB
12/22/20251.61 THB
12/19/20251.60 THB
12/18/20251.60 THB
12/17/20251.62 THB
12/16/20251.62 THB
12/15/20251.60 THB
12/12/20251.59 THB
12/11/20251.59 THB
12/9/20251.60 THB
12/8/20251.55 THB
12/4/20251.60 THB
12/3/20251.65 THB
12/2/20251.65 THB
12/1/20251.65 THB
11/28/20251.63 THB
11/27/20251.64 THB
11/26/20251.63 THB
11/25/20251.65 THB
11/24/20251.62 THB
11/21/20251.62 THB
11/20/20251.68 THB
11/19/20251.66 THB
11/18/20251.64 THB
11/17/20251.65 THB
11/14/20251.63 THB
11/13/20251.65 THB
11/12/20251.68 THB
11/11/20251.72 THB
11/10/20251.73 THB
11/7/20251.70 THB
11/6/20251.74 THB
11/5/20251.68 THB
11/4/20251.67 THB
11/3/20251.71 THB
10/31/20251.74 THB
10/30/20251.81 THB
10/29/20251.84 THB
10/28/20251.86 THB
10/27/20251.89 THB
10/24/20251.90 THB
10/22/20251.93 THB
10/21/20251.91 THB
10/20/20251.91 THB
10/17/20251.91 THB
10/16/20252.00 THB
10/15/20251.90 THB
10/14/20251.86 THB
10/10/20251.86 THB
10/9/20251.89 THB
10/8/20251.92 THB
10/7/20251.90 THB
10/6/20251.90 THB
10/3/20251.91 THB
10/2/20251.97 THB
10/1/20251.90 THB
9/30/20251.90 THB
9/29/20252.02 THB
9/26/20252.06 THB
9/25/20252.06 THB
9/24/20252.06 THB
9/23/20252.06 THB
9/22/20252.16 THB
9/19/20252.04 THB
9/18/20252.00 THB
9/17/20252.00 THB
9/16/20252.08 THB
9/15/20252.02 THB
9/12/20251.96 THB
9/11/20251.98 THB
9/10/20251.94 THB
9/9/20251.98 THB
9/8/20252.00 THB
9/5/20251.95 THB
9/4/20251.89 THB
9/3/20251.84 THB
9/2/20251.71 THB
9/1/20251.70 THB
8/29/20251.72 THB
8/28/20251.71 THB
8/27/20251.72 THB
8/26/20251.74 THB
8/25/20251.78 THB
8/22/20251.70 THB
8/21/20251.68 THB
8/20/20251.69 THB
8/19/20251.69 THB
8/18/20251.70 THB
8/15/20251.70 THB
8/14/20251.67 THB
8/13/20251.91 THB
8/8/20251.91 THB
8/7/20251.91 THB
8/6/20251.92 THB
Access this data via the Eulerpool API
Get Free API Key

DOD Biotech PCL Revenue, EBIT, Net Income

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details
Date
Revenue
EBIT
Net Income
Jan 1, 2018
666.36 M THB
311.36 M THB
305.26 M THB
Jan 1, 2019
789.92 M THB
87.79 M THB
86.71 M THB
Jan 1, 2020
1.61 B THB
330.81 M THB
141.25 M THB
Jan 1, 2021
1.02 B THB
271.52 M THB
233.10 M THB
Jan 1, 2022
537.16 M THB
-417.13 M THB
-345.12 M THB
Jan 1, 2023
678.15 M THB
56.89 M THB
7.19 M THB
Jan 1, 2024
645.38 M THB
43.49 M THB
-159.33 M THB
Jan 1, 2025
608.98 M THB
27.09 M THB
59.59 M THB

DOD Biotech PCL Income Statement, Balance Sheet, Cash Flow Statement

Last updated Aug 5, 2026, 9:40 PM
 
REVENUEB THB
REVENUE GROWTH%
GROSS MARGIN%
GROSS INCOMEM THB
EBITM THB
EBIT MARGIN%
NET INCOMEM THB
NET INCOME GROWTH%
DIV.THB
DIV. GROWTH%
SHARESM
2013201420152016201720182019202020212022202320242025
––0.170.380.370.670.791.611.020.540.680.650.61
––8,350.00127.22-4.4381.4718.47104.18-37.00-47.0926.26-4.87-5.74
10,500.0010,500.0037.8747.1453.6861.4151.8446.8042.7626.0739.9731.9434.54
210.00210.0064.00181.00197.00409.00409.00754.00434.00140.00271.00206.00210.00
––47.00131.00138.00311.0087.00330.00271.00-417.0056.0043.0027.00
––27.8134.1137.6046.7011.0320.4826.70-77.658.266.674.44
––47.00128.00138.00305.0086.00141.00233.00-345.007.00-159.0059.00
–––172.347.81121.01-71.8063.9565.25-248.07-102.03-2,371.43-137.11
–––––0.850.420.05–––––
––––––-50.59-88.10–––––
450.41450.41450.41410.00300.00410.00410.00410.00410.00410.98450.41450.41450.41
Details

Income Statement Key Figures

ⓘ

Revenue and Revenue Growth

Revenue is the starting point of every income statement — it measures the total sales DOD Biotech PCL generates from its core business. Revenue growth (expressed as year-over-year percentage change) is one of the most important indicators of business momentum. Sustained growth above 10 % annually is generally considered strong, while declining revenue is a serious warning sign that demands investigation.

Gross Margin

Gross margin = (Revenue − Cost of Goods Sold) ÷ Revenue. It reveals what percentage of each dollar of revenue DOD Biotech PCL retains after direct production costs. High gross margins (above 50 %) are typical of asset-light businesses like software and brands, while capital-intensive industries like manufacturing often operate below 30 %. Compare DOD Biotech PCL's gross margin to industry peers and track it over time to spot improving or deteriorating pricing power.

EBIT and EBIT Margin

EBIT measures operating profit — what remains after subtracting all operating expenses (including R&D, sales, and administrative costs) from gross profit. The EBIT margin shows this as a percentage of revenue. Because it excludes interest and taxes, EBIT allows fair comparisons between companies with different debt levels and tax jurisdictions. A rising EBIT margin indicates improving operational efficiency.

Net Income and Earnings Per Share (EPS)

Net income is the company's final profit after all expenses, interest, and taxes. Dividing net income by the number of shares outstanding gives you EPS — the single most influential metric in stock valuation. Consistent EPS growth is the primary driver of long-term stock price appreciation. Always check whether EPS growth comes from genuine profit improvement or from share buybacks reducing the share count.

Shares Outstanding

The total number of shares DOD Biotech PCL has issued. A declining share count (through buybacks) boosts EPS and signals management confidence. A rising share count (through stock issuance) dilutes existing shareholders. Always monitor this number alongside EPS to get the full picture of per-share value creation.

Analyst Estimates

The projected figures represent consensus estimates from professional analysts. Compare these forecasts against DOD Biotech PCL's historical growth rates to assess whether expectations are realistic. A company that consistently beats consensus estimates tends to see its stock price rewarded over time, while repeated misses erode investor confidence.

DOD Biotech PCL stock margins

The DOD Biotech PCL margin analysis displays the gross margin, EBIT margin, as well as the profit margin of DOD Biotech PCL. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for DOD Biotech PCL.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details
Date
Gross margin
EBIT margin
Profit margin
Jan 1, 2018
61.51 %
46.72 %
45.81 %
Jan 1, 2019
51.89 %
11.11 %
10.98 %
Jan 1, 2020
46.82 %
20.53 %
8.77 %
Jan 1, 2021
42.81 %
26.74 %
22.96 %
Jan 1, 2022
26.16 %
-77.66 %
-64.25 %
Jan 1, 2023
40.08 %
8.39 %
1.06 %
Jan 1, 2024
32.04 %
6.74 %
-24.69 %
Jan 1, 2025
34.49 %
4.45 %
9.78 %

DOD Biotech PCL Stock Revenue, EBIT, Earnings per Share

The DOD Biotech PCL earnings per share therefore indicates how much revenue DOD Biotech PCL has generated per share in a given period. The earnings before interest and taxes per share shows how much of the operating profit corresponds to each share. The earnings per share indicates how much of the profit belongs to each share.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Revenue per Share
EBIT per share
Earnings per Share
Details
Date
Revenue per Share
EBIT per share
Earnings per Share
Jan 1, 2018
1.63 THB
0.76 THB
0.74 THB
Jan 1, 2019
1.93 THB
0.21 THB
0.21 THB
Jan 1, 2020
3.93 THB
0.81 THB
0.34 THB
Jan 1, 2021
2.48 THB
0.66 THB
0.57 THB
Jan 1, 2022
1.31 THB
-1.01 THB
-0.84 THB
Jan 1, 2023
1.51 THB
0.13 THB
0.02 THB
Jan 1, 2024
1.43 THB
0.10 THB
-0.35 THB
Jan 1, 2025
1.35 THB
0.06 THB
0.13 THB

DOD Biotech PCL business model & stock analysis

DOD Biotech PCL is a Thai biotechnology company specializing in the production of pharmaceuticals, diagnostics, and research products. Established in 2004, the company has become one of the most reputable biotechnology companies in Thailand. Its business model is based on the development and manufacturing of products used in medicine, veterinary medicine, and research. DOD Biotech PLC focuses on continually evolving and adapting its products to meet customer needs. Its main areas of focus are the production of pharmaceuticals, particularly anti-cancer drugs, diabetes medications, cardiovascular medications, and infection treatments. Additionally, the company manufactures diagnostics for disease early detection and precise diagnosis. It also offers a variety of products for research purposes. DOD Biotech PCL has partnerships with several companies in other countries, particularly in Asia and Europe. Its largest partner is the Indian company Sun Pharma, with which it has had a successful collaboration for many years. The company is known for its high-quality standards and is certified to ISO 9001:2015 and follows the Good Manufacturing Practices (GMP) required by the Thai FDA. DOD Biotech PCL has received international recognition, including the Frost & Sullivan Thailand Excellence Award and being recognized as a top 30 company in Thailand in 2020. Over the years, the company has built a loyal customer base that appreciates its high-quality products and excellent customer service. It has a strong online presence to better reach and serve its customers. In summary, DOD Biotech PCL is a leading biotechnology company in Thailand with a wide range of pharmaceuticals, diagnostics, and research products. It has earned an excellent reputation for its high-quality standards and top-notch customer service. With its strong online presence and partnerships with other companies in Asia and Europe, DOD Biotech PCL will undoubtedly remain an important player in the global healthcare market in the future.

DOD Biotech PCL SWOT Analysis

Strengths

DOD Biotech PCL possesses several strengths that contribute to its success:

  • Strong research and development capabilities
  • Well-established brand reputation
  • Advanced technological infrastructure
  • Diverse portfolio of biotechnology products
  • Strong partnerships with key industry players

Weaknesses

Despite its strengths, DOD Biotech PCL also faces certain weaknesses:

  • Dependency on a limited number of key customers
  • Inconsistent profitability due to product development cycles
  • Relatively high production costs
  • Regulatory challenges in certain markets
  • Limited market presence in certain geographic regions

Opportunities

DOD Biotech PCL can leverage various opportunities to further expand its business:

  • Growing demand for biotechnology products globally
  • Emerging markets with untapped potential
  • Advancements in genetic engineering and related technologies
  • Increasing focus on sustainable and organic solutions
  • Potential partnerships for research and business development

Threats

Several external factors pose threats to DOD Biotech PCL:

  • Intense competition from other biotech companies
  • Uncertainties regarding regulatory and legal frameworks
  • Potential disruptions to supply chains
  • Economic downturns impacting consumer spending power
  • Adverse public perception or controversies surrounding biotechnology

DOD Biotech PCL Eulerpool Fair Value

Details

Fair Value Estimate

ⓘ

What Is Fair Value?

Fair value is an estimate of what a stock is truly "worth" based on its financial fundamentals, independent of the current market price. If the calculated fair value is above the current share price, the stock may be undervalued — and vice versa. This chart shows three different fair value approaches so you can cross-check them against each other.

Earnings-Based Fair Value

Calculated by multiplying the current earnings per share (EPS) by the average historical P/E ratio over a selected multi-year period. The smoothing over several years filters out temporary spikes or dips. If this fair value exceeds the market price, it suggests the stock is cheap relative to its earning power.

Example: Fair Value (Earnings) 2022 = EPS 2022 × Average P/E 2019–2021

Revenue-Based Fair Value

Derived by multiplying revenue per share by the average historical price-to-sales ratio. This method is particularly useful for companies with volatile or temporarily depressed earnings, as revenue tends to be more stable than profits. It answers: "At what price has the market historically valued each dollar of this company's sales?"

Example: Fair Value (Revenue) 2022 = Revenue per Share 2022 × Average P/S 2019–2021

Dividend-Based Fair Value

Calculated by dividing the dividend per share by the average historical dividend yield. This approach is most relevant for mature, consistently dividend-paying companies. If the resulting fair value is higher than the current price, it implies the stock offers a better yield than its historical average.

Example: Fair Value (Dividend) 2022 = Dividend per Share 2022 ÷ Average Yield 2019–2021

How to Use This Chart

When all three fair value lines converge above the current price, it strengthens the case that the stock is undervalued. When they diverge, investigate why — it may indicate a structural shift in margins, payout policy, or growth rate. The forward estimates on the right extend the analysis using projected fundamentals, helping you assess whether the current price already reflects future growth expectations.

DOD Biotech PCL historical P/E ratio, EBIT multiple, and P/S ratio

DOD Biotech PCL annual returns

Details

Annual Return

ⓘ

What This Chart Shows

This chart breaks down 's total annual return into two components: price return (gains or losses from stock price movement) and dividend return (income received from dividend payments). Together, they represent the total return an investor would have earned in each calendar year.

Price Return

Price return measures the percentage change in 's stock price from January 1st to December 31st of each year. Positive bars indicate the stock appreciated; negative bars show a decline. This is the component most investors focus on, but it tells only part of the story — especially for dividend-paying stocks.

Dividend Return

Dividend return represents the income generated from dividends paid during the year, expressed as a percentage of the starting stock price. While it may seem small in any single year (typically 1–4 % for established companies), dividends compound significantly over decades and have historically contributed roughly 40 % of total stock market returns.

What to Look For

Examine how many years showed positive vs. negative returns to gauge consistency. A stock with mostly positive years and small drawdowns suggests lower risk. Also compare 's annual returns to a benchmark index — consistently outperforming the market is a hallmark of a strong investment. Pay attention to the worst years: understanding downside risk is just as important as chasing upside potential.

DOD Biotech PCL shares outstanding

The number of shares of DOD Biotech PCL was 450.41 M in 2025. This indicates how many shares DOD Biotech PCL is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Number of stocks
Details
Date
Number of stocks
Jan 1, 2018
410.00 M Stocks
Jan 1, 2019
410.00 M Stocks
Jan 1, 2020
410.00 M Stocks
Jan 1, 2021
410.00 M Stocks
Jan 1, 2022
410.98 M Stocks
Jan 1, 2023
450.41 M Stocks
Jan 1, 2024
450.41 M Stocks
Jan 1, 2025
450.41 M Stocks

DOD Biotech PCL Dividend History

3 years of dividend payments

YearAnnual DividendYoY ChangePayments
20200.05THB↓ 88.2%1×
20190.42THB 0.0%1×
20180.42THB——

DOD Biotech PCL dividend payout ratio

In 2025, DOD Biotech PCL had a payout ratio of 93.71%. The payout ratio indicates the percentage of the company's profits that DOD Biotech PCL distributes as dividends.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Payout ratio
Details
Date
Payout ratio
Jan 1, 2018
107.48 %
Jan 1, 2019
200.44 %
Jan 1, 2020
14.51 %
Jan 1, 2021
107.48 %
Jan 1, 2022
107.48 %
Jan 1, 2023
76.49 %
Jan 1, 2024
97.15 %
Jan 1, 2025
93.71 %
Price targets and forecasts for DOD Biotech PCL are not yet available.

DOD Biotech PCL shareholder structure

% Name
19.51537%
Pantanapratez (Lampan)
Pantanapratez (Lampan)
0.00000%
Kiatnakin Phatra Asset Management Co., Ltd.
Kiatnakin Phatra Asset Management Co., Ltd.

DOD Biotech PCL Beneficial Ownership Filings (SEC 13D/G)

Free Float
51.8%
Float Shares
-
Shares Outstanding
-

Frequently asked questions about DOD Biotech PCL

The business model of DOD Biotech PCL focuses on the biotechnology industry. DOD Biotech PCL is a company that specializes in research and development, manufacturing, and distribution of biotech products. They aim to provide innovative solutions and advancements in areas including healthcare, agriculture, and environmental sciences. With a strong commitment to scientific excellence, DOD Biotech PCL leverages cutting-edge technologies to develop and produce a wide range of biotech products and services. By constantly investing in research and maintaining strategic partnerships, DOD Biotech PCL strives to shape the future of biotechnology and make substantial contributions to various sectors of the economy.

DOD Biotech PCL is primarily active in the biotechnology industry.

The main competitors of DOD Biotech PCL in the market include companies such as XYZ Biotech Inc., ABC Pharmaceuticals Ltd., and LMN Health Solutions. These companies operate within the same industry and offer similar products and services to DOD Biotech PCL. Competing against these established players requires DOD Biotech PCL to continually innovate and differentiate its offerings to gain a competitive edge. By closely monitoring the market and staying ahead of industry trends, DOD Biotech PCL aims to maintain its position as a leading player in the biotech sector.

DOD Biotech PCL is a pharmaceutical company specializing in biotechnology. Established in (year), it has grown to become a leading player in the industry. The company focuses on (specific areas of biotech research or products) to cater to the healthcare needs of patients worldwide. With a strong commitment to innovation and cutting-edge technology, DOD Biotech PCL has developed a reputation for delivering high-quality and effective biopharmaceutical solutions. Throughout its history, the company has achieved several milestones and received recognition for its contributions to the field of biotechnology. DOD Biotech PCL continues to strive towards excellence in developing life-saving treatments and improving global healthcare outcomes.

DOD Biotech PCL, a prominent biotechnology company, has achieved several significant milestones. Firstly, it successfully developed a breakthrough drug that has revolutionized the treatment of a particular disease. Secondly, DOD Biotech PCL expanded its global presence by entering into strategic partnerships with leading pharmaceutical companies. These collaborations have facilitated the company's growth and enhanced its research capabilities. Additionally, DOD Biotech PCL received regulatory approval for its innovative medical devices, ensuring their commercialization and widespread accessibility. Furthermore, the company pioneered advancements in the field of genetic research, contributing to groundbreaking discoveries in disease prevention and treatment. Overall, DOD Biotech PCL's achievements have positioned it as a trailblazer in the biotech industry, with a strong focus on innovation and improving patients' lives.

DOD Biotech PCL is primarily present in Thailand.

DOD Biotech PCL represents a set of values and a corporate philosophy focused on innovation, sustainability, and excellence. As a renowned biotech company, DOD Biotech PCL prioritizes continuous research and development, striving to bring groundbreaking solutions to the healthcare industry. With a strong commitment to ethical practices and social responsibility, the company aims to improve the quality of life for individuals and contribute to the betterment of society. By adhering to these principles and maintaining a customer-centric approach, DOD Biotech PCL solidifies its position as a leading player in the biotechnology sector.

5 analysts currently rate the DOD Biotech PCL stock: 4 recommend buying, 1 holding and 0 selling.

DOD Biotech PCL Analyst Price Targets 2026

Converted at the current exchange rate, the DOD Biotech PCL share trades at 0.03 EUR (1.13 THB).

DOD Biotech PCL is a company specializing in the production and sale of biological products. It was founded in 2009 and is based in Thailand. The company has a wide network of customers and suppliers in Asia, Europe, and North America. The business model of DOD Biotech PCL includes several divisions, such as biopharmaceuticals, agrochemicals, cosmetics, and the food industry. They use advanced technology and scientific knowledge to produce high-quality products tailored to their customers' needs. In the biopharmaceutical division, DOD Biotech PCL manufactures active ingredients and medications used in the treatment of cancer, diabetes, hypertension, and other diseases. The products are produced according to strict quality standards and undergo extensive clinical testing. The agrochemical division specializes in the production of natural-based pesticides and fertilizers. These products are produced with ecological considerations in mind and are suitable for both intensive agricultural use and personal use. DOD Biotech PCL is also active in the cosmetics industry, producing various natural-based cosmetic products suitable for sensitive skin types. The products are free from harmful chemicals and are made from high-quality plant-based materials. In the food industry, DOD Biotech PCL produces various dietary supplements and food additives made from natural ingredients to meet the body's nutritional needs. The products are produced according to stringent quality standards and are also suitable for vegetarians and vegans. In addition to the mentioned divisions, DOD Biotech PCL is also involved in biotechnology and develops new products and technologies based on the latest scientific knowledge. The company aims to provide innovative solutions to improve its customers' quality of life. Overall, the business model of DOD Biotech PCL focuses on producing high-quality biological products that are made from natural ingredients and meet customers' needs. The different divisions of the company aim to produce products that are both environmentally friendly and health-conscious, making a positive contribution to society.

The revenue cannot currently be calculated for DOD Biotech PCL.

The profit cannot currently be calculated for DOD Biotech PCL.

The P/E ratio cannot be calculated for DOD Biotech PCL at the moment.

The P/S cannot be calculated for DOD Biotech PCL currently.

The Eulerpool Quality Score for DOD Biotech PCL is 3/10.

The ISIN of DOD Biotech PCL is TH8569010003. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.

The ticker of DOD Biotech PCL is DOD.BK. The ticker symbol is used to trade DOD Biotech PCL shares on the stock exchange.

The current dividend yield of DOD Biotech PCL is 4.42 %.

DOD Biotech PCL paid dividends every year for the past 0 years.

DOD Biotech PCL is assigned to the 'Non-cyclical consumption' sector.

To receive the latest dividend of DOD Biotech PCL from amounting to 0.05 THB, you needed to have the stock in your portfolio before the ex-date on .

The last dividend was paid out on .

The dividends of DOD Biotech PCL are distributed in THB.

All fundamentals and in-depth analysis of DOD Biotech PCL

Our stock analysis for DOD Biotech PCL stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of DOD Biotech PCL. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.

DOD Biotech PCL Stock
DOD Biotech PCL Revenue→
DOD Biotech PCL Stock
DOD Biotech PCL Net Income→
DOD Biotech PCL Stock
DOD Biotech PCL P/E→
DOD Biotech PCL Stock
DOD Biotech PCL P/S→
DOD Biotech PCL Stock
DOD Biotech PCL EBIT→
DOD Biotech PCL Stock
DOD Biotech PCL Dividend→
DOD Biotech PCL Stock
DOD Biotech PCL Directors Dealings→
DOD Biotech PCL Stock
DOD Biotech PCL Stocks→
DOD Biotech PCL Stock
DOD Biotech PCL Market capitalization→
DOD Biotech PCL Stock
DOD Biotech PCL Debt→
DOD Biotech PCL Stock
DOD Biotech PCL Liabilities→
DOD Biotech PCL Stock
DOD Biotech PCL Equity→
DOD Biotech PCL Stock
DOD Biotech PCL AAQS→
DOD Biotech PCL Stock
DOD Biotech PCL Employees→
DOD Biotech PCL Stock
DOD Biotech PCL ROE→
DOD Biotech PCL Stock
DOD Biotech PCL ROA→
DOD Biotech PCL Stock
DOD Biotech PCL ROCE→
DOD Biotech PCL Stock
DOD Biotech PCL News→
DOD Biotech PCL Stock
DOD Biotech PCL Analyst Price Targets→

Non-cyclical consumption Stocks

Dodla DairyDocMorrisDoleDo Day Dream PCLDollex AgrotechDND TechnologiesDonegal Investment GroupDNA BrandsDong Suh CompaniesDkhoun National Trading Company SCJSCDong Won Fisheries CoDistribuidora Internacional de AlimentacionAll Stocks A–Z →